|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
March 11, 2006
Serono in turmoil as Glaxo quits bid
>> "THE $15bn sale of Serono was this weekend plunged into turmoil with a decision by GlaxoSmithKline to abandon talks to buy the Swiss group". Serono’s hopes of a sale faded further late last week after it became clear that the group’s lead product would soon face increased competition. Rebif, its key multiple sclerosis treatment, will be forced to fight for market leadership with Elan Corporation’s Tysabri. |